JEAN WELSH: Open Payments
NPI 1861592461 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,359 in 91 payments from 23 companies in 2025. Trend: 2023 $3,101 · 2024 $2,294 · 2025 $2,359
Food & beverage: $2,339Education: $20
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $454 |
| Novo Nordisk Inc | 7 | $218 |
| Ardelyx, Inc. | 8 | $215 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $195 |
| Gilead Sciences, Inc. | 7 | $172 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $133 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $121 |
| Lilly USA, LLC | 5 | $120 |
| Amgen Inc. | 6 | $118 |
| Cumberland Pharmaceuticals, Inc. | 3 | $75 |
Products named: AIRSUPRA, IBSRELA, CAPLYTA, Ozempic, Kerendia, JARDIANCE, MOUNJARO, OTEZLA.
Industry payments across MD — which companies pay providers there.
